Top Page
Hansoh Pharmaceutical Group Company Limited
(3692)
Hansoh Pharmaceutical Group Company Limited (3692) vs. iShares MSCI Hong Kong ETF (EWH)
Hansoh Pharmaceutical Group Company Limited Business Overview & Revenue Model
Hansoh Pharmaceutical Group Company Limited Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 13.19B | 12.26B | 10.10B | 9.38B | 9.94B | 8.69B |
| Gross Profit | 11.98B | 11.16B | 9.07B | 8.51B | 9.06B | 7.89B |
| EBITDA | 4.79B | 4.28B | 4.20B | 2.93B | 3.08B | 2.99B |
| Net Income | 4.78B | 4.37B | 3.28B | 2.58B | 2.71B | 2.57B |
Balance Sheet | ||||||
| Total Assets | 35.07B | 31.66B | 33.04B | 30.00B | 27.16B | 20.79B |
| Cash, Cash Equivalents and Short-Term Investments | 27.12B | 23.39B | 24.86B | 21.63B | 18.94B | 13.73B |
| Total Debt | 116.86M | 117.89M | 4.30B | 4.38B | 3.83B | 92.75M |
| Total Liabilities | 3.97B | 2.98B | 7.24B | 7.35B | 7.13B | 2.92B |
| Stockholders Equity | 31.10B | 28.68B | 25.79B | 22.65B | 20.03B | 17.88B |
Cash Flow | ||||||
| Free Cash Flow | 1.06B | 3.64B | 2.90B | 2.47B | 2.12B | 962.83M |
| Operating Cash Flow | 1.18B | 3.86B | 3.12B | 2.74B | 2.58B | 2.39B |
| Investing Cash Flow | -3.76B | -1.39B | 1.07B | -5.94B | -2.26B | -2.87B |
| Financing Cash Flow | -1.87B | -6.07B | -753.70M | -818.14M | 3.42B | -1.04B |
Hansoh Pharmaceutical Group Company Limited Technical Analysis
Hansoh Pharmaceutical Group Company Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | $43.00B | 9.65 | 7.86% | 7.32% | 1.13% | -13.53% | |
| ― | $34.35B | 12.45 | 14.91% | 3.88% | -0.45% | 9.00% | |
| ― | HK$29.00B | 13.76 | 12.65% | 3.20% | 10.56% | -13.58% | |
| ― | HK$30.72B | 10.10 | 5.90% | 2.70% | ― | ― | |
| ― | $80.78B | 18.09 | 6.75% | 1.48% | -1.12% | 76.16% | |
| ― | HK$210.60B | 40.06 | 16.09% | 1.06% | 8.68% | 0.82% | |
| ― | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
Hansoh Pharmaceutical Group Company Limited Corporate Events
Hansoh Pharmaceutical Group Company Limited announced that its New Drug Application for HS-10365 capsules, a RET inhibitor for treating RET fusion-positive non-small cell lung cancer, has been accepted by China’s National Medical Products Administration. This development marks a significant step in Hansoh’s drug development efforts, potentially enhancing its position in the oncology market and offering new treatment options for lung cancer patients.
The most recent analyst rating on (HK:3692) stock is a Hold with a HK$38.00 price target. To see the full list of analyst forecasts on Hansoh Pharmaceutical Group Company Limited stock, see the HK:3692 Stock Forecast page.
Hansoh Pharmaceutical Group has entered into a license agreement with F. Hoffmann-La Roche Ltd, granting Roche an exclusive worldwide license to develop, manufacture, and commercialize Hansoh’s investigational CDH17-targeting antibody-drug conjugate, HS-20110, for colorectal cancer and other solid tumors. This agreement, which excludes the Chinese Mainland, Hong Kong, Macau, and Taiwan, involves an upfront payment of $80 million and potential milestone payments up to $1.45 billion, along with tiered royalties on future sales. This strategic partnership is expected to enhance Hansoh’s scientific and commercial capabilities, positioning it favorably in the global pharmaceutical market.
The most recent analyst rating on (HK:3692) stock is a Hold with a HK$37.00 price target. To see the full list of analyst forecasts on Hansoh Pharmaceutical Group Company Limited stock, see the HK:3692 Stock Forecast page.
Hansoh Pharmaceutical Group Company Limited has announced an interim cash dividend of HKD 0.2316 per share for the six months ending June 30, 2025. This update includes changes to the timeline for lodging transfer documents for registration, the book close period, and the record date. The dividend will be paid on October 30, 2025, and reflects the company’s ongoing financial health and commitment to shareholder returns.
The most recent analyst rating on (HK:3692) stock is a Hold with a HK$37.00 price target. To see the full list of analyst forecasts on Hansoh Pharmaceutical Group Company Limited stock, see the HK:3692 Stock Forecast page.
Hansoh Pharmaceutical Group Company Limited announced a rescheduling of dates related to its interim dividend for the six months ended June 30, 2025, due to unstable weather conditions. The changes affect the timeline for lodging transfer documents, the book closure period, and the record date, but the payment date remains unchanged. This adjustment ensures the company maintains its operational commitments despite external challenges.
The most recent analyst rating on (HK:3692) stock is a Hold with a HK$37.00 price target. To see the full list of analyst forecasts on Hansoh Pharmaceutical Group Company Limited stock, see the HK:3692 Stock Forecast page.
Hansoh Pharmaceutical Group Company Limited announced that its innovative drug XINYUE (Inebilizumab Injection) received approval from the National Medical Products Administration of China for a second indication, targeting immunoglobulin G4-related disease in adults. This approval, which follows a priority review, enhances the company’s product offerings and strengthens its position in the pharmaceutical market, potentially benefiting stakeholders by expanding treatment options for patients.
The most recent analyst rating on (HK:3692) stock is a Buy with a HK$40.00 price target. To see the full list of analyst forecasts on Hansoh Pharmaceutical Group Company Limited stock, see the HK:3692 Stock Forecast page.
Hansoh Pharmaceutical Group Company Limited announced the placement of 108,000,000 new shares under a general mandate, with the shares priced at HK$36.30 each. This placement is expected to generate gross proceeds of approximately HK$3,920.40 million, which will be used for purposes detailed in the company’s announcement. The placement represents about 1.82% of the company’s total shares in issue and is subject to certain conditions and approvals. The move is part of the company’s strategy to strengthen its financial position and support its operational goals.
The most recent analyst rating on (HK:3692) stock is a Buy with a HK$39.93 price target. To see the full list of analyst forecasts on Hansoh Pharmaceutical Group Company Limited stock, see the HK:3692 Stock Forecast page.
Hansoh Pharmaceutical Group Company Limited announced an interim dividend of HKD 0.2316 per share for the six months ending June 30, 2025. The dividend will be paid on October 30, 2025, and reflects the company’s strong financial performance and commitment to delivering value to its shareholders. This announcement may positively impact the company’s market position and investor confidence.
The most recent analyst rating on (HK:3692) stock is a Buy with a HK$34.83 price target. To see the full list of analyst forecasts on Hansoh Pharmaceutical Group Company Limited stock, see the HK:3692 Stock Forecast page.
Hansoh Pharmaceutical Group reported a 14.3% increase in revenue for the first half of 2025, driven by innovative drugs and collaborative products, which accounted for 82.7% of total revenue. Key achievements include FDA Breakthrough Therapy Designation for a B7-H3-targeted ADC and multiple drug approvals by the NMPA, enhancing the company’s market position and growth prospects.
The most recent analyst rating on (HK:3692) stock is a Buy with a HK$34.83 price target. To see the full list of analyst forecasts on Hansoh Pharmaceutical Group Company Limited stock, see the HK:3692 Stock Forecast page.
Hansoh Pharmaceutical Group Company Limited has announced a board meeting scheduled for August 18, 2025, to consider and approve the interim results for the first half of the year and discuss the recommendation of an interim dividend. This meeting is significant as it may impact the company’s financial strategies and stakeholder interests.
The most recent analyst rating on (HK:3692) stock is a Buy with a HK$34.83 price target. To see the full list of analyst forecasts on Hansoh Pharmaceutical Group Company Limited stock, see the HK:3692 Stock Forecast page.